Document Detail

Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy.
MedLine Citation:
PMID:  8400346     Owner:  NLM     Status:  MEDLINE    
Forty patients with chemotherapy-related diarrhea were randomized to receive (i) octreotide 0.5 mg three times per day s.c. or (ii) loperamide 4 mg three times per day p.o. until complete remission of diarrhea was achieved. In the octreotide group 80% of patients showed complete resolution of loose bowel movements within 4 days of therapy, while in the loperamide group this goal was obtained in only 30% of cases (p < 0.001). If after 4 days no benefit was seen, patients were considered to have failed antidiarrheal therapy. Failure was recorded in only one case (5%) treated with s.c. octreotide and in five patients (25%) who received loperamide. The mean duration of antidiarrheal therapy necessary to achieve remission was 3.4 days in the octreotide group and 6.1 days in the loperamide group (p < 0.001). Treatment with octreotide was very well tolerated with mild abdominal pain in 15% of cases and pain in the injection site in 15% of patients. Subcutaneous octreotide is highly effective in the management of chemotherapy-related diarrhea in cancer patients.
V Gebbia; I Carreca; A Testa; R Valenza; G Curto; G Cannata; N Borsellino; M A Latteri; C Cipolla; M Florena
Related Documents :
22922696 - Short- and long-term outcomes in octogenarians after coronary artery bypass surgery.
23582506 - Prospective outcome study of 106 cases of vertical mastopexy, augmentation/mastopexy, a...
23856086 - Health-related quality of life changes following major and minor hepatic resection: the...
23448976 - Cool excimer laser-assisted angioplasty (cela) and tibial balloon angioplasty (tba) in ...
23025336 - The mozart effect in patients suffering from tinnitus.
23233826 - Treatment of partial thickness burns with zn-hyaluronan: lessons of a clinical pilot st...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Anti-cancer drugs     Volume:  4     ISSN:  0959-4973     ISO Abbreviation:  Anticancer Drugs     Publication Date:  1993 Aug 
Date Detail:
Created Date:  1993-11-15     Completed Date:  1993-11-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9100823     Medline TA:  Anticancer Drugs     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  443-5     Citation Subset:  IM    
University of Palermo, Chair and Service of Chemotherapy, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Diarrhea / chemically induced*,  drug therapy*
Injections, Subcutaneous
Loperamide / adverse effects,  therapeutic use*
Middle Aged
Neoplasms / drug therapy
Octreotide / adverse effects,  therapeutic use*
Reg. No./Substance:
53179-11-6/Loperamide; 83150-76-9/Octreotide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Bioavailability of a new oral formulation of medroxyprogesterone acetate compared with the standard ...
Next Document:  XB596, a promising bis-naphthalimide anti-cancer agent.